Tirzepatide (RUO)

Also known as: LY3298176, GIP/GLP-1 dual agonist

Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide with a 39-residue backbone modified by two aminoisobutyric acid substitutions and a C20 fatty diacid conjugated at Lys20 for albumin binding.

Research context

Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide with a 39-residue backbone modified by two aminoisobutyric acid substitutions and a C20 fatty diacid conjugated at Lys20 for albumin binding. In research settings it is used to probe balanced dual-incretin receptor activity and to benchmark selectivity assays against pure GLP-1 agonists. Supplied strictly as a laboratory research reference.

Storage & stability

Store lyophilized at -20°C, protected from light. Reconstituted at 2–8°C, use within 4 weeks.

Purity & testing standards

Each batch of Tirzepatide (RUO) is analyzed by an independent third-party laboratory. Standard release testing includes reverse-phase HPLC at 220 nm (purity target HPLC ≥99%), electrospray mass spectrometry (identity confirmation), and endotoxin screening. Batch numbers on each vial resolve to a downloadable COA on this site.